Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

被引：0

作者：

Schmid, P. ^{[1
]}

McArthur, H. L. ^{[2
]}

Cortes, J. ^{[3
,4
]}

Xu, B. ^{[5
]}

Cardoso, F. ^{[6
]}

Casalnuovo, M. L. ^{[7
]}

Demirci, U. ^{[8
]}

Freitas, R., Jr. ^{[9
]}

Ghosh, J. ^{[10
]}

Hegg, R. ^{[11
]}

Iwata, H. ^{[12
]}

Chuken, Y. A. Lopez ^{[13
]}

Nechaeva, M. ^{[14
]}

Robson, M. E. ^{[15
]}

Villalobos Valencia, R. ^{[16
]}

Lloyd, A. ^{[17
]}

D'Cruz, C. ^{[18
]}

Foxley, A. ^{[18
]}

Park, Y. H. ^{[19
]}

机构：

[1] Queen Mary Univ, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] UT Southwestern Med Ctr, Dallas, TX USA

[3] IBCC, Pangaea Grp, Barcelona, Spain

[4] IOB Madrid, Inst Oncol, Barcelona, Spain

[5] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[6] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[7] CENIT Ctr Med Neurociencias, Buenos Aires, DF, Argentina

[8] Mem Ankara Hosp, Ankara, Turkiye

[9] Hosp Araujo Jorge, Goiania, Go, Brazil

[10] Tata Med Ctr, Kolkata, India

[11] Sao Paulo State Govt Womens Hlth Reference Ctr, Sao Paulo, Brazil

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] ICAN Oncol Ctr, Monterrey, Mexico

[14] Arkhangelsk Reg Clin Oncol Dispensary, Arkhangelsk, Russia

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[16] Consultorio Ctr Torre Med Dalinde, Oncol Med, Mexico City, DF, Mexico

[17] AstraZeneca, Oncol R&D, Cambridge, England

[18] AstraZeneca, Oncol R&D, Waltham, MA USA

[19] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA19

引用

页码：1212 / 1213

页数：2

共 50 条

[41] Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)
Dent, Rebecca
Im, Seock-Ah
Espie, Marc
Blau, Sibel
Tan, Antoinette R.
Isakoff, Steven J.
Oliveira, Mafalda
Saura, Cristina
Wongchenko, Matthew
Kapp, Amy V.
Chan, Wai Y.
Singel, Stina M.
Maslyar, Daniel J.
Baselga, Jose
Kim, Sung-Bae
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
F Cappuzzo
F Mazzoni
A Gennari
S Donati
B Salvadori
C Orlandini
G L Cetto
A Molino
E Galligioni
M Mansutti
S Tumolo
A Lucentini
F Valduga
S Bartolini
L Crinò
P F Conte
British Journal of Cancer, 2004, 90 : 31 - 35
[43] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
Cappuzzo, F
Mazzoni, F
Gennari, A
Donati, S
Salvadori, B
Orlandini, C
Cetto, GL
Molino, A
Galligioni, E
Mansutti, M
Tumolo, S
Lucentini, A
Valduga, F
Bartolini, S
Crinò, L
Conte, PF
BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
[44] AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial
Schmid, Peter
Abraham, Jacinta
Chan, Stephen
Wheatley, Duncan
Brunt, Murray
Nemsadze, Gia
Baird, Richard
Park, Yeon Hee
Hall, Peter
Perren, Timothy
Stein, Robert C.
Laszlo, Mangel
Ferrero, Jean-Marc
Phillips, Melissa
Conibear, John
Sarker, Shah-Jalal
Prendergast, Aaron
Cartwrightx, Hayley
Mousa, Kelly
Turner, Nicholas C.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Jiang, Zefei
Ouyang, Quchang
Sun, Tao
Zhang, Qingyuan
Teng, Yuee
Cui, Jiuwei
Wang, Haibo
Yin, Yongmei
Wang, Xiaojia
Zhou, Xin
Wang, Yongsheng
Sun, Gang
Wang, Jingfen
Zhang, Lili
Yang, Jin
Qian, Jun
Yan, Min
Liu, Xinlan
Yi, Tienan
Cheng, Ying
Li, Man
Zang, Aimin
Wang, Shusen
Wang, Chuan
Wu, Xinhong
Cheng, Jing
Li, Hui
Lin, Ying
Geng, Cuizhi
Gu, Kangsheng
Xie, Chunwei
Xiong, Huihua
Wu, Xiaohong
Yang, Junlan
Li, Qingshan
Chen, Yiding
Li, Fanfan
Zhang, Anqin
Zhang, Yongqiang
Wu, Yudong
Nie, Jianyun
Liu, Qiang
Wang, Kun
Mo, Xueli
Chen, Lilin
Pan, Yueyin
Fu, Peifen
Zhang, Helong
Pang, Danmei
Sheng, Yuan
NATURE MEDICINE, 2024, 30 (02) : 249 - 256
[46] Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer
Wongchenko, Matthew J.
Kim, Sung-Bae
Saura, Cristina
Oliveira, Mafalda
Lipson, Doron
Kennedy, Mark
Greene, Mandy
Breese, Virginia
Mani, Aruna
Xu, Na
Dent, Rebecca
JCO PRECISION ONCOLOGY, 2020, 4 : 1012 - 1024
[47] Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
Yuan, Yuan
Yost, Susan E.
Cui, Yujie
Ruel, Christopher
Murga, Mireya
Tang, Aileen
Martinez, Norma
Schmolze, Daniel
Waisman, James
Patel, Niki
Vora, Lalit
Tumyan, Lusine
Bozoghlanian, Mari
Stewart, Daphne
Frankel, Paul H.
ONCOLOGIST, 2023, 28 (07): : E498 - E507
[48] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang
Quchang Ouyang
Tao Sun
Qingyuan Zhang
Yuee Teng
Jiuwei Cui
Haibo Wang
Yongmei Yin
Xiaojia Wang
Xin Zhou
Yongsheng Wang
Gang Sun
Jingfen Wang
Lili Zhang
Jin Yang
Jun Qian
Min Yan
Xinlan Liu
Tienan Yi
Ying Cheng
Man Li
Aimin Zang
Shusen Wang
Chuan Wang
Xinhong Wu
Jing Cheng
Hui Li
Ying Lin
Cuizhi Geng
Kangsheng Gu
Chunwei Xie
Huihua Xiong
Xiaohong Wu
Junlan Yang
Qingshan Li
Yiding Chen
Fanfan Li
Anqin Zhang
Yongqiang Zhang
Yudong Wu
Jianyun Nie
Qiang Liu
Kun Wang
Xueli Mo
Lilin Chen
Yueyin Pan
Peifen Fu
Helong Zhang
Danmei Pang
Yuan Sheng
Nature Medicine, 2024, 30 : 249 - 256
[49] TREATMENT PATTERNS OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) IN US COMMERCIAL PLANS
Jiang, S.
Hill, K.
Varghese, D.
Waldeck, R.
Botteman, M.
VALUE IN HEALTH, 2017, 20 (05) : A127 - A127
[50] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Yardley, Denise A.
Brufsky, Adam
Coleman, Robert E.
Conte, Pierfranco F.
Cortes, Javier
Glueck, Stefan
Nabholtz, Jean-Mark A.
O'Shaughnessy, Joyce
Beck, Robert M.
Ko, Amy
Renschler, Markus F.
Barton, Debora
Harbeck, Nadia
TRIALS, 2015, 16

← 1 2 3 4 5 →